Daily News
-
More patients show interest in joint replacement
Lisa Mandl, MD, MPH, said that joint replacement would be an option for a growing portion of patients with either rheumatic disease or osteoarthritis.
-
Comfort level about warfarin replacements still low
Rheumatologists see patients on direct oral anticoagulants on a regular basis, but management of these medications is still a bit outside their specialty and comfort zone, said Kerry Stone, MD.
-
The right tech tools improve rheumatology practices
“Every ten minutes of computer time we can automate is another ten minutes we can spend with patients,” said Paul Sufka, MD.
-
Learn how to answer SpA patients’ tough questions
Robert Inman, MD, Professor of Medicine and Immunology at University Health Network and University of Toronto, will offer the latest data and current thinking in response to common patient questions during Current State of the Art in Spondyloarthritides (SpA): Tough Questions Your SpA Patients Might…
-
Interest in wearable biosensors outpaces research
Brennan Spiegel, MD, MSHS,will discuss some of the unexpected insights coming from one of the first formal rheumatology studies incorporating wearable biosensors during a clinical symposium on Monday.
-
Rheumatology close to seeing influx of biosimilars
Joseph E. Huffstutter, MD, will offer a preview of the ever-changing regulatory journey for biosimilars during a clinical symposium. Two dozen biosimilars have been approved worldwide, Dr. Huffstutter said.
-
Emotional support for rheumatology patients lacking
“Providing psychological support is part of our task under guidelines, but there is evidence that this is not happening,” said Sarah Hewlett, PhD, MA, RN. “There is quite a lot of evidence that we are not.”
-
Experts reconsider value of serial ANCA testing for many patients
Antibody testing results don’t offer simple black-or-white answers. A positive antinuclear antibody (ANA) test does not lead to an automatic diagnosis of autoimmune rheumatic disease, and multiple anti-neutrophil cytoplasmic antibody (ANCA) testing is not always clinically helpful or even appropriate.
-
Incorporating patient into treatment discussion is important for arthritis self-management
There was a time when what passed for arthritis patient education was the clinician simply telling the patient about the condition.
-
New targeted biologics emerge as the next generation of rheumatologic therapies
Biologics are a relatively new class of drugs that have been used and studied for almost 20 years, and many new targeted biologics known as bDMARDs have emerged with the promise of not only providing better treatment for rheumatic diseases, but also the potential of…